Skinvisible, Inc. (SKVI)

OTCMKTS: SKVI · Delayed Price · USD
0.690
+0.589 (583.17%)
Jul 19, 2024, 4:00 PM EDT - Market closed
Market Cap 3.13M
Revenue (ttm) 20,000
Net Income (ttm) -1.16M
Shares Out 4.54M
EPS (ttm) -0.26
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 100
Open 0.690
Previous Close 0.101
Day's Range 0.690 - 0.690
52-Week Range 0.055 - 0.755
Beta 0.15
Analysts n/a
Price Target n/a
Earnings Date n/a

About SKVI

Skinvisible, Inc., together with its subsidiaries, focuses on the development, manufacture, and sale of topical, transdermal, and mucosal polymer-based delivery system technologies and formulations for use in pharmaceutical, over-the-counter, personal skincare, and cosmetic arenas. Its non-dermatological formulations offer solutions for women’s health, pain management, and other markets. The company’s flagship product is Invisicare, a patented polymer delivery system technology that enhances the delivery of active ingredients for topically appl... [Read more]

IPO Date Jan 7, 1999
Employees 2
Stock Exchange OTCMKTS
Ticker Symbol SKVI
Full Company Profile

Financial Performance

In 2023, Skinvisible's revenue was $20,000, a decrease of -92.84% compared to the previous year's $279,296. Losses were -$2.38 million, 7.74% more than in 2022.

Financial Statements

News

Promising Data on Transdermal Obesity Formulations Announced by Skinvisible

Results Demonstrate Significant Transdermal Performance of GLP-1 Receptor Agonists and CB-1 Receptor Antagonists Using Invisicare Technology LAS VEGAS, NV / ACCESSWIRE / July 11, 2024 / Skinvisible Ph...

10 days ago - Accesswire

Skinvisible Expands Obesity Patent Application for Transdermal Delivery

Innovative Delivery System Shows Promise for GLP-1 Agonists, CB-1 Antagonists, and SGLT-2 Inhibitors LAS VEGAS, NV / ACCESSWIRE / June 24, 2024 / Skinvisible Pharmaceuticals, Inc. (OTCQB:SKVI), an inn...

27 days ago - Accesswire

Skinvisible Announces Significant Progress in Licensee's Clinical Trials for Invisicare Formulation Targeting Nethertons Syndrome

LAS VEGAS, NV / ACCESSWIRE / February 14, 2024 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI) is excited to share a promising update on the ongoing clinical trials conducted by its licensee, Quoin P...

Other symbols: QNRX
5 months ago - Accesswire

Skinvisible Announces First Invisicare Delivery Technology Product to Receive U.S. FDA Acceptance of Investigational New Drug

LAS VEGAS, NV / ACCESSWIRE / June 6, 2022 / Skinvisible, Inc. ("Skinvisible") (OTCQB:SKVI), is pleased to announce that its licensee Quoin Pharmaceuticals, Inc. ("Quoin") (NASDAQ:QNRX), has received U...

2 years ago - Accesswire